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Tobramycin population pharmacokinetics . 
in neonates 
Objective: To establish a tobramycin dosing schedule for neonates of various gestational ages. 
Methods: This was a retrospective study with prospective validation. A retrospective study in 470 neonates, 
with suspected septicemia in the first week of life, was performed. All patients received tobramycin 
according to the following scheme: neonates with a gestational age of less than 28 weeks received 3.5 
mg/kg every 24 hours, neonates from 28 to 36 weeks received 2.5 mg/kg every 18 hours, neonates older 
than 36 weeks received 2.5 mg/kg every 12 hours. Trough and peak tobramycin serum levels were 
determined before drug administration and 30 minutes after the fourth dose. Tobramycin data were 
analyzed according to a one-compartment open model with use of NONMFJM population pharmacoki- 
netic software. Individual empirical Bayes estimates were generated on the basis of the population esti- 
mates and used to calculate predicted peak and trough levels for different doses and dosing intervals. To 
establish au optimal dosing regimen, target trough levels were set at below 2 mg/L and target peak levels 
were set above 5 to 10 mg/L. The dosing regimen was prospectively evaluated in 23 patients. 
Results: Of the 470 patients, 19.1% of measured peak and 32.8% of measured trough tobramycin serum 
levels were outside the desired therapeutic range, and 48.8% of neonates with a gestational age of less than 
28 weeks had an aberrant trough level. With use of population estimates, the following dosing regimen 
was recommended: gestational age below 32 weeks, 4 mg/kg every 48 hours; gestational age between 32 
and 37 weeks, 4 mg/kg every 36 hours, gestational age above 37 weeks, 4 mg/kg every 24 hours. With this 
dosing schedule, predicted peak levels were higher than 5 mg/L in 95.1% of the neonates. Predicted 
trough levels were higher than 2 mg/L in 1.9% of the neonates and higher than 1 mg/L in 7.6%. 
Prospectively measured peak levels were higher than 5 mg/L in all but one infant. Measured trough levels 
were higher than 2 mg/L in three patients and marginally higher than 1 mg/L in four patients. 
Concl&ons: With the use of this proposed schedule, taking into account differences in gestational ages, 
predicted peak levels will be therapeutic, whereas predicted trough levels will minimize toxicity. (Clin 
Pharmacol Ther 1997;62:392-9.) 
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During recent years there has been much debate 
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rum concentrations of aminoglycosides to maximize 
efficacy and minimize toxicity in adults.lm5 Efficacy of 
aminoglycosides is related to the ratio of peak serum 
concentration to the minimal inhibitory concentra- 
tion (MIC) of the infecting microorganism and the 
area under the time versus concentration curve 
(AUC),iP5 whereas toxicity of these drugs seems to 
be related to high trough levels.rP5 On the basis of 
these pharmacodynamic characteristics and the re- 
sults of clinical trials, it was recently advocated in 
three meta-analytic studies2P4S5 that aminoglycosides 
be administered once daily to adults. 
Aminoglycosides also play an important role in 
the initial empiric treatment of neonatal septice- 
mia.6 Various regimens for dose, dosing interval, 
and monitoring have been suggested and imple- 
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mented over the last two decades.7-14 A significant 
relation between gestational age and the need for 
prolonged dosing intervals was established, and the 
more recent dosing regimens propose once daily 
dosing of aminoglycosides in very low birth weight 
infants.“-i5 However, we had the impression that 
high trough levels were frequently encountered in 
these infants even with once daily administration of 
aminoglycosides. We therefore performed this study 
to investigate the results of the dosing schedule we 
currently use to find a more appropriate dosing 
schedule to administer aminoglycosides to newborns 
of different gestational ages during the first week of 
life. Using population pharmacokinetics on our own 
data over the last few years, we established a dosing 
regimen that combined optimal efficacy with mini- 
mal toxicity. To validate this regimen, we prospec- 
tively tested it in our patient group. 
PATIENTS AND METHODS 
Patients. This retrospective study with prospec- 
tive validation comprised all neonates in the first 
week of life who were treated with tobramycin as 
part of their empiric treatment for suspected neo- 
natal sepsis in the neonatal intensive care unit of 
the Sophia Children’s Hospital between August 
1992 and December 1994. Only neonates whose 
paired peak and trough serum tobramycin levels 
were available were included. In the period be- 
tween February and April 1997, additional pa- 
tients were studied for validation. 
Parameters. All parameters were abstracted from 
the patient files. Gestational ages and birth weights 
were recorded. Gestational age was determined on 
the basis of the mother’s menstrual history, con- 
firmed by early ultrasound examinations if available, 
and by physical examination with the use of the 
criteria of Dubowitz et a1.i6 
Administration and dosage regimen of tobramycin. 
Tobramycin was given in combination with 50 to 100 
mg/kg/day amoxicillin (INN, amoxicilline) as em- 
piric treatment for suspected neonatal sepsis. Pa- 
tients with documented invasive bacterial infection 
received intravenous therapy for at least 10 days. 
Patients with sterile cultures and without a focus of 
infection received therapy for a total of 72 hours. 
Administration of tobramycin was done in a 30- 
minute intravenous infusion with the following dos- 
ing regimen: gestational age ~28 weeks, 3.5 mg/ 
kg/24 hours; gestational age from 28 to 36 weeks, 2.5 
mg/kg/l8 hours; gestational age >36 weeks, 2.5 mg/ 
kg/12 hours. 
All doses and times of administration were recorded 
routinely. Trough and peak blood samples were taken 
before and 30 minutes after the fourth dose. Dosage 
adjustments were made according to the outcome, 
with the intention to keep trough levels below 2 mgLL 
and peaks between 4 and 10 mg/L. 
Analytical techniques. Concentrations of tobramy- 
tin were measured by a Fluorescence Polarization 
Assay with use of a TDxFLx (Abbott Diagnostic 
Division, Amstelveen, The Netherlands). 
Data analysis, dosage recommendations, and simu- 
lations. Tobramycin data were analyzed according 
to a one-compartment open model, assuming the 
data were attributable to the fourth dose after 
birth, with use of NONMEM population pharma- 
cokinetics software (NONMEM version IV, 
NONMEM project group, University of Califor- 
nia, San Francisco, Calif.). On the basis of the 
population estimates, individual empirical Bayes 
estimates were generated. Scatterplots against 
weight and age indicated that both clearance and 
volume of distribution were related to age and 
weight. After estimation of clearance per kilo- 
gram for birth weights, only a correlation between 
volume of distribution and age or weight re- 
mained (age and weight are naturally highly cor- 
related in this group). The empirical Bayes esti- 
mates were used to calculate predicted peak and 
trough levels at steady state for different dose and 
dose interval combinations, and scatterplots 
against gestational age were constructed. 
Target serum tobramycin levels were set. The target 
trough level was below 2 mg/L (generally accepted as 
trough when administering a drug more than once 
daily) and preferably below 1 rngL4,17 Target peak 
levels were set at a minimum of 5 mg/L dailyl’-‘l and 
preferably 10 times the MIC of the infecting microor- 
ganism because of the possibility of emergence of 
aminoglycoside-resistant pathogens at lower ra- 
tios.21,22 The MIC of the most important gram- 
negative pathogen, Escherichia coli, is 1 mg/L in the 
Dutch population,” so target peak levels were 5 to 10 
mgn* 
Prospective study. The predictive performance of 
the dosing regimen was evaluated prospectively in 
patients receiving tobramycin according to the dos- 
ing recommendation mentioned in the results: 
l Gestational age 132 weeks: 4 mgkg every 48 hours 
l Gestational age >32 weeks but <37 weeks: 4 
mg/kg every 36 hours 
l Gestational age ~37 weeks: 4 mg/kg every 24 hours 
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Table I. Measured tobramycin concentrations 
Tobramycin 
(mglL) 
Gestational age groups (wk) 
GA < 28 28 5 GA < 32 32 I GA < 37 GA > 37 Total 
Trough I 2 42 (51.3%) 103 (61.7%) 104 (81.2%) 67 (72.1%) 316 (67.2%) 
Trough > 2 40 (48.8%) 64 (38.3%) 24 (18.8%) 26 (28.0%) 154 (32.8%) 
Peak<5 4 (4.9%) 37 (22.2%) 32 (25.0%) 17 (18.3%) 90 (19.1%) 
5 5 Peak % 10 75 (91.5%) 128 (76.6%) 96 (75.0%) 74 (79.6%) 373 (79.4%) 
Peak > 10 3 (3.7%) 2 (1.2%) 0 (0%) 2 (2.2%) 7 (1.5%) 
TOTAL 82 (17.4%) 167 (35.5%) 128 (27.2%) 93 (19.8%) 470 (100%) 
GA, Gestational age. 
Numbers are the number of patients; numbers in parentheses are the percentages of the total in the group. 
Tobramycin peak and trough serum levels were 
determined 30 minutes after the first dose and just 
before the second dose and were analyzed as de- 
scribed in the retrospective study. 
RESULTS 
Retrospective study. Four hundred seventy neo- 
nates were enrolled in the study. Their gestational 
ages and birth weights ranged from 23 to 42 weeks 
(median age, 31.5 weeks) and from 485 to 5245 gm 
(median weight, 1530 gm), respectively. 
Table I summarizes the results of tobramycin 
peak and trough concentrations for the different 
gestational age groups. As shown in Table I, 
19.1% of peak levels and 32.8% of trough levels 
were outside the desired therapeutic range. In the 
gestational age groups ~28 weeks and between 28 
and 32 weeks, the percentage of aberrant trough 
levels was particularly high-48.8% and 38.3%, 
respectively. 
On the basis of the scatterplots and set target serum 
tobramycm levels, the dosing is recommended at 4 
mg/kg with the following dosing intervals: 
l Gestational age 532 weeks: 4 mg,ikg every 48 hours 
l Gestational age ~32 but ~37 weeks: 4 mg/kg 
every 36 hours 
l Gestational age ~37 weeks: 4 mgkg every 24 hours 
For illustrative purposes, the curves predicted 
with use of the advised dosing regimen and the 
empirical Bayes estimates were constructed and 
concentrations corresponding to the 5th, 50th, 
and 95th percentiles computed for the three dos- 
ing interval-age groups (Fig. 1). Calculations were 
performed with SPSS for Windows (version 6.1.2). 
Fig. 2 and Table II show the predicted peak and 
trough levels with these recommendations. Fig. 2 
clearly shows that predicted peak levels rose with 
gestational age. Predicted peak levels ranged from 
2.9 to 18.7 mg/L, with a median of 8.0 mg/L. 
Predicted peak levels were below 5 mg/L in 4.9% 
of the newborns and above 10 mg/L in 27.9% of 
the newborns. Median peak levels in the gesta- 
tional age groups were 6.1 mg/L in the group ~28 
weeks old, 7.3 mg/L in the group aged between 28 
and 32 weeks, 8.7 mg/L in the group aged between 
32 and 37 weeks, and 13.2 in the term group. 
Insufficient peak levels were found in 11 of 82 
(13.4%) of neonates with a gestational age ~28 
weeks. Of these 11 newborns, 10 had predicted 
peak levels between 4 and 5 mg/L. Predicted 
trough levels ranged from 0.01 to 8.1 mg/L (me- 
dian, 0.36 mg/L). Trough levels were above 2 mg/L 
in 1.9% of all patients and between 1 and 2 mg/L 
in 5.7%. As Fig. 2 shows, there was no relation 
between gestational age and trough levels. Fig. 1 
shows the predicted serum levels over time for the 
three gestational age groups. The 50th percentile 
line of tobramycin serum levels dropped below 1 
mg/L at approximately 18,24, and 32 hours in the 
groups that received tobramycin once every 24, 
36, and 48 hours, respectively. 
Prospective study. Prospective evaluation was 
performed in 23 neonates. Their gestational ages 
ranged from 24.4 to 42.1 weeks (median, 32.5 
weeks). Table III summarizes the results of ob- 
served tobramycin peak and trough concentra- 
tions for the different gestational age groups with 
use of the recommended dosing regimen. Peak 
levels ranged from 2.9 to 13.5 mg/L, with a median 
of 7.9 mg/L. Only one peak level was below 5 
mg/L. Median peak levels in the gestational age 
groups were 6.9 mg/L in the group ~32 weeks old, 
7.3 mg/L in the group aged between 32 and 37 
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weeks, and 9.0 in the term group. Trough levels 
were between 0.1 and 5.7 mg/L (median, 0.7 
mg/L). High trough levels were found in seven 
patients. Of these, three patients had trough levels 
of 1.2 mg/L and one patient had a trough level of 
1.3 mg/L. Median trough levels in the gestational 
age groups were 0.7 mg/L in the group ~32 weeks 
old, 0.65 mg/L in the group aged between 32 and 
37 weeks, and 0.95 mg/L in the term group. 
DISCUSSION 
Earlier investigations of the pharmacokinetics 
of aminoglycosides and other drugs in neonates 
have shown that elimination half-lives are longer 
in neonates, especially in preterm neonates.8-11’24 
This is primarily the result of a higher percent- 
age of body water and thus a larger volume of 
distribution and reduced clearance.25,26 Most dos- 
ing schedules for preterm and term neonates take 
this into account.7-12’14 We had the clinical im- 
pression that our use of gestational age-related 
dosing still led to serum concentrations that were 
frequently outside the desired range. The inven- 
tory of our own results over the past few years 
showed that about one third of the initial trough 
serum levels were too high, particularly in prema- 
tures neonates, and that in view of these results a 
more appropriate dosing schedule should be 
found. 
The limitation of administration of aminoglyco- 
sides to neonates lies in the long elimination half- 
life; therefore the only way to effectively reduce 
trough serum levels without compromising ade- 
quate peak levels is by further increasing the dos- 
ing interval. It is difficult to define the desired 
therapeutic range for aminoglycosides. Peak lev- 
els of >4 to 5 mg/L are generally accepted as 
necessary for antibacterial efficacy with adminis- 
tration three times a daylgm21; however, questions 
are being raised about the underlying fundament 
of this assumption.3 What is known is that efficacy 
of aminoglycosides is related to the peak level/ 
MIC ratio and AUClT21 and that in vitro ratios of 
10: 1 prevent emergence of aminoglycoside- 
resistant pathogens.22 In the first week of life, the 
pathogens for which tobramycin is indicated as 
therapy are mainly acquired through the birth 
passage. By far the most common pathogen in this 
group of gram-negative bacteria is E. coli.27 In a 
recent survey of the Dutch population, the MIC,, 
for E. coli was found to be 1 mg/L,23 and although 
in theory a peak serum concentration of 10 mg/L 
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Fig. 1. Predicted tobramycin concentration curves with 
revised dosing recommendation. A, 4 mgikg every 24 
hours. B, 4 mgkg every 36 hours. C, 4 mg.ikg every 48 
hours. Curves are 95th, 5Oth, and 5th percentiles. 
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Fig. 2. Predicted tobramycin peak (squares) and trough (circles) levels with revised dosing 
recommendation. 
Table II. Predicted tobramycin concentrations with use of revised dosing recommendation 
Gestational age groups (wk) 
Tobramycin (mglL) GA -=c 28 28 I GA =C 32 32 5 GA < 37 GA 2 37 Total 
Trough 5 1 75 (91.5%) 161 (96.4%) 116 (90.6%) 
1 < Trough 5 2 6 (7.3%) 5 (3.0%) 9 (7.0%) 
Trough > 2 1 (1.2%) 1 (0.6%) 3 (2.3%) 
Peak < 5 11(13.4%) 10 (6.0%) 2 (1.6%) 
5 I Peak 5 10 69 (84.1%) 149 (89.2%) 92 (71.9%) 
Peak > 10 2 (2.4%) 8 (4.8%) 34 (26.6%) 
TOTAL 82 (17.4%) 167 (35.5%) 128 (27.2%) 
82 (88.2%) 434 (92.3%) 
7 (7.5%) 27 (5.7%) 
4 (4.3%) 9 (1.9%) 
0 (0.0%) 23 (4.9%) 
6 (6.5%) 316 (67.2%) 
87 (93.5%) 131 (27.9%) 
93 (19.8%) 470 (100%) 
GA, Gestational age. 
Numbers are the number of patients; numbers in parentheses are the percentages of the total in the group. 
would be optimal, a peak/MIC ratio of 5 can be 
considered to be effective. 
The effect of serum concentrations on toxicity is 
even harder to quantify. High aminoglycoside 
peak levels do not increase nephrotoxicity be- 
cause of drug-specific saturable uptake.28-30 In 
several large meta-analytical studies, toxicity 
seems to be related to high predose levels, indi- 
cating that trough levels are not low long enough 
to prevent renal accumulation.“275’19 Commonly 
accepted trough level goals are <2 mg/L, but for 
once-a-day administration, most authors keep 
1 mg/L as a safe limit.4’17 Another point in the 
discussion is that renal toxicity is mostly revers- 
ible, whereas ototoxicity is usually irreversible. 
Most authors suggest that ototoxicity is related to 
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Table III. Measured tobramycin concentrations with use of revised dosing recommendation 
Gestational age groups (wk) 
Tobramycin (mgJL) GA<32 321GA<37 GA237 Total 
Trough I 1 6(85.7%) 5 (62.5%) 
1 < Trough I 2 - 2(25.0%) 2 (25.0%) 4 (17.4%) 
Trough > 2 1 (14.3%) 1 (12.5%) 1 (12.5%) 3 (13.0%) 
Peak < 5 1 (14.3%) - - 1 (4.3%) 
5 5 Peak I 10 6(85.7%) 7 (87.5%) 6 (75.0%) 19(82.6%) 
Peak > 10 - 1 (12.5%) 2(25.0%) 3 (13.0%) 
TOTAL 7 (30.4%) 8 (34.8%) 8 (34.8%) 23 (100%) 
GA, Gestational age. 
Numbers are the number of patients; numbers in parentheses are the percentages of the total in the group. 
total dose and duration of therapy rather than to 
serum aminoglycoside levels, but the relation to 
aminoglycoside serum levels remains unclear. 
This form of toxicity usually occurs in patients 
who have received either long or repeated courses 
of aminoglycosides.3 Reports about ototoxicity in 
neonates are contradictory. Some authors report 
no relation,31-33 whereas others did find a higher 
incidence.34-36 Until conclusive evidence is given, 
it seems prudent to keep the duration of tobra- 
mycin therapy as short as possible. 
On the grounds of a peak/MIC ratio above 10 and 
the MIC,, of E. coli in our population, a peak 
tobramycin serum concentration as high as 10 mg/L 
is desirable from the efficacy point of view. A trough 
level below 1 mg/L will have to suffice until better 
data about toxicity are available. 
Using population pharmacokinetics, we estab- 
lished a better dosing scheme to meet these criteria. 
This resulted in the following gestational age- 
related regimen: 
l Gestational age 132 weeks: 4 mg/kg/48 hours 
l Gestational age >32 weeks but ~37 weeks: 4 
mg/kg/36 hours 
l Gestational age >37 weeks: 4 mg/kg/24 hours 
With this regimen most predicted peak levels 
were in the required range in neonates with a 
gestational age above 32 weeks, with acceptable 
predicted trough values for almost all (Table II). 
In the gestational age group below 28 weeks, pre- 
dicted peak serum levels were arguably too low in 
12 of 82 patients, but 11 of these were between 4 
to 5 mg/L. The prospective evaluation showed that 
serum peak levels were in the desired therapeutic 
range in all but one patient (Table III). Measured 
trough levels were mildly elevated in four patients 
and clearly too high in three, so there is a definite 
need for measuring trough serum levels before the 
second dose. This dosing regimen also makes re- 
dundant the need for a loading dose of aminogly- 
cosides in premature neonates, as suggested by 
some researchers,11,17,37 because high enough 
peak levels are achieved at the first dose. In ad- 
dition, the practical advantage of this proposed 
schedule is a fixed starting dose per kilogram of 
body weight, irrespective of gestational age. 
A possible problem in the group that received 
tobramycin once every 48 hours is that tobramycin 
levels might be subtherapeutic for too long. Twenty- 
four-hour serum levels in this group (Fig. 1) show 
that levels in most neonates were around 2 mg/L 
(which is still higher than the MIC of relevant mi- 
croorganisms) but dropped below 1 mg/L after ap- 
proximately 32 hours. In the prospective group of 23 
patients, serum trough levels did not fall too low. 
Furthermore, there is also the post-antibiotic effect, 
or post-antibiotic leukocyte enhancement effect, or 
sub-MIC effect, which will prevent regrowth of bac- 
teria at sub-MIC levels of tobramycin for another 
period of at least hours,38-40 so we consider this to be 
a safe dosing interval. 
In conclusion, the information that we presented 
shows that acceptable therapeutic tobramycin peak 
and trough concentrations can be reached with a 
simple dosing schedule for three separate gesta- 
tional age groups in the first week of life. Trough 
levels according to our scheme are not toxic and 
probably not long enough below 1 kg/ml to permit 
bacterial regrowth. 
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